Biomerica (BMRA) Posts Earnings Results, Misses Estimates By $0.02 EPS

Biomerica (NASDAQ:BMRA) announced its quarterly earnings data on Monday. The company reported ($0.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.02), Fidelity Earnings reports. The company had revenue of $1.26 million for the quarter, compared to analyst estimates of $1.58 million. Biomerica had a negative net margin of 36.36% and a negative return on equity of 45.72%.

NASDAQ:BMRA opened at $2.46 on Wednesday. Biomerica has a 12-month low of $1.60 and a 12-month high of $4.33. The stock has a market capitalization of $23.92 million, a P/E ratio of -14.47 and a beta of 1.35.

WARNING: This article was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://sportsperspectives.com/2019/04/17/biomerica-bmra-posts-earnings-results-misses-estimates-by-0-02-eps.html.

Biomerica Company Profile

Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.

Featured Article: What is the float in trading stocks?

Earnings History for Biomerica (NASDAQ:BMRA)

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.